Search Result

Results for "

pan inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (15) AMPK (2) Amyloid-β (2) Antibiotic (8) Apoptosis (38) ATM/ATR (1) Aurora Kinase (2) Autophagy (14) Bacterial (11) Bcl-2 Family (3) Bcr-Abl (4) Beta-lactamase (4) Btk (2) c-Fms (1) c-Kit (2) Caspase (10) CDK (3) COX (1) Cyclophilin (1) Dengue virus (3) Deubiquitinase (1) DNA/RNA Synthesis (3) Dopamine Transporter (1) Early 2 Factor (E2F) (1) EGFR (14) Epigenetic Reader Domain (11) ERK (1) FGFR (6) Filovirus (3) Flavivirus (5) FLT3 (1) GLUT (1) HCN Channel (1) HCV (7) HCV Protease (2) HDAC (15) HIF/HIF Prolyl-Hydroxylase (3) Histone Acetyltransferase (1) Histone Demethylase (4) HIV (1) HPV (3) HSP (1) IAP (1) Influenza Virus (5) Integrin (1) Isocitrate Dehydrogenase (IDH) (1) JAK (5) Ligands for E3 Ligase (1) MARCKS (1) MDM-2/p53 (2) MEK (1) Mitochondrial Metabolism (1) Mitophagy (3) MMP (2) Monoamine Oxidase (2) Monoamine Transporter (1) mTOR (9) NADPH Oxidase (2) Necroptosis (1) Notch (2) NTPDase (3) Organoid (3) Oxidative Phosphorylation (1) P-selectin (1) p38 MAPK (1) PAK (1) Parasite (3) PDGFR (1) PDHK (2) PDI (2) Phosphatase (3) Phosphodiesterase (PDE) (1) PI3K (22) Pim (10) PIN1 (1) PKC (6) PKD (3) Polo-like Kinase (PLK) (1) PPAR (2) PROTAC Linkers (1) PROTACs (3) Proteasome (1) Protein Arginine Deiminase (2) Raf (17) Ras (25) Reactive Oxygen Species (1) Ribosomal S6 Kinase (RSK) (1) ROCK (2) Salt-inducible Kinase (SIK) (3) SARS-CoV (6) Ser/Thr Protease (2) Serotonin Transporter (1) SHP2 (2) Sirtuin (1) Src (2) SRPK (1) STAT (1) TAM Receptor (2) TGF-β Receptor (1) Tie (1) Topoisomerase (3) Trk Receptor (7) VEGFR (5) Virus Protease (5) YAP (3) YB-1 (1) γ-secretase (1)
By Research Areas:	Cancer (214) Cardiovascular Disease (3) Endocrinology (2) Infection (44) Inflammation/Immunology (32) Metabolic Disease (3) Neurological Disease (10)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (4)

281

Inhibitors & Agonists

Screening Libraries

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101295

Pan-RAS-IN-1 5 Publications Verification	Ras	Cancer
Pan-RAS-IN-1 is a *pan-Ras* inhibitor that disrupts the interaction of Ras proteins and their effectors.

HY-163594

Pan-RAS-IN-3	Ras	Cancer
Pan-RAS-IN-3 is a *pan-Ras* inhibitor, and can be used for study of melanoma and acute myeloid leukaemia .

HY-148098

Pan KRas-IN-1	Ras	Cancer
Pan KRas-IN-1 is a pan KRas inhibitor, can be used for agent resistance in cancer developed with KRas G12C inhibitors .

HY-10082

Triapine 4 Publications Verification 3-AP; pan-811; OCX191	DNA/RNA Synthesis	Cancer
Triapine (3-AP; PAN-811) is a potent inhibitor of the M2 subunit of ribonucleotide reductase (RR), and is a potent radiosensitizer.

HY-142452

Pan-RAF kinase inhibitor 1	Raf	Cancer
Pan-RAF kinase inhibitor 1 is a potent inhibitor of Pan-RAF kinase. Pan-RAF kinase inhibitor 1 regulates MAPK signaling by inhibiting RAF kinase, thereby exerting an effect on the proliferation of RAS-mutant tumor cells. Pan-RAF kinase inhibitor 1 has the potential for the research of cancer diseases (extracted from patent WO2021110141A1, compound 16B) .

HY-156555

pan-KRAS-IN-3	Ras	Cancer
pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor. pan-KRAS-IN-3 can be used for research of cancers . pan-KRAS-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163489

pan-KRAS-IN-15	Ras	Cancer
pan-KRAS-IN-15 (compound 58) is a pan-KRAS inhibitor. pan-KRAS-IN-15 can be used in pancreatic cancer research .

HY-163488

pan-KRAS-IN-14	Ras	Cancer
pan-KRAS-IN-14 (compound 20) is a *Pan-KRAS* inhibitor (IC₅₀ =2.3 nM) .

HY-164802

Pan-RAS-IN-7	Ras	Cancer
Pan-RAS-IN-7 (Compound D101) is a pan RAS inhibitor that can be used for the synthesis of ADCs. Pan-RAS-IN-7 can be utilized in cancer research .

HY-163147

PAN endonuclease-IN-1	Influenza Virus	Infection
PAN endonuclease-IN-1 (Compound 23) is a potent PAN endonuclease inhibitor, with K_d values of 277 μM, 384 μM and 328 μM for WT, I38T and E23K PA_N endonucleases, respectively. The RNA-dependent RNA polymerase acidic N-terminal (PAN) endonuclease, a critical component of influenza viral replication machinery, is an antiviral target .

HY-163299

pan-KRAS-IN-5	Ras Apoptosis	Cancer
pan-KRAS-IN-5 (compound 15a) is a pan-KRAS translation inhibitor by targeting 5′-UTR RNA G-quadruplexes (rG4s). pan-KRAS-IN-5 induces cell cycle arrest and promptes apoptosis in KRAS-driven cancer cells .

HY-164645

pan-KRAS-IN-16	Ras	Cancer
pan-KRAS-IN-16 (Compound 3344) is an anti-RAS small molecule derived from an intracellular antibody fragment with pan-RAS-effector protein-protein interaction inhibitor properties. pan-KRAS-IN-16 binds to a hydrophobic pocket near to the effector-binding switch regions of RAS. pan-KRAS-IN-16 prevents endogenous RAS-dependent signaling in tumor cell lines .

HY-10082B

Triapine hydrochloride 3-AP hydrochloride; pan-811 hydrochloride; OCX191 hydrochloride	DNA/RNA Synthesis	Cancer
Triapine (hydrochloride) is the hydrochloride form of Triapine (HY-10082). Triapine (3-AP; PAN-811) is a potent inhibitor of the M2 subunit of ribonucleotide reductase (RR), and is a potent radiosensitizer .

HY-P10243

Ac-VAD-CMK	Caspase	Neurological Disease
Ac-VAD-CMK is a pan inhibitor for caspase 1 .

HY-162439

pan-KRAS-IN-6	Ras	Cancer
pan-KRAS-IN-6 (compound 12) is a potent pan KRAS inhibitor with IC₅₀ values of 9.79 nM (Kras G12D) and 6.03 nM (Kras G12V) .

HY-163595

Pan-RAS-IN-4	Ras	Cancer
Pan-RAS-IN-4 (compound 2) is a potent inhibitor of RAS, with the IC₅₀ of ＜ 100 nM for KRAS G12D. Pan-RAS-IN-4 plays an important rile in cancer research .

HY-158028

PAN endonuclease-IN-2	Influenza Virus	Infection
PAN endonuclease-IN-2 (compound T-31) is a *PA_N* endonuclease inhibitor (IC₅₀: 0.15 μM) and antiviral agent with broad-spectrum anti- Influenza activity. PAN is the N-terminal PA subunit of the polymerase-RNA complex and the dependent endonuclease (CEN) active site. PAN initiates RNA replication by promoting cleavage of the RNA strand and allowing the polymerase to begin synthesizing new RNA molecules. PAN endonuclease-IN-2 targets both the influenza HA and RdRp complexes, thereby interfering with viral entry into host cells and viral replication .

HY-12419

BMS-983970	Notch	Cancer
BMS-983970 is an oral pan-Notch inhibitor for the treatment of multiplecancers .

HY-112802A

AZD3229 Tosylate	c-Kit	Cancer
AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.

HY-100020

BAY-1436032 3 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.

HY-144677

pan-HER-IN-2	EGFR Apoptosis	Cancer
pan-HER-IN-2 (Compound C6) is a reversible, orally active pan-HER inhibitor with IC₅₀ values of 0.72, 2.0, 8.2 and 75.1 nM against EGFR, HER4, EGFR ^T790M/L858R and HER2, respectively. pan-HER-IN-2 induces apoptosis and shows antitumor activities .

HY-144676

pan-HER-IN-1	EGFR Apoptosis	Cancer
pan-HER-IN-1 (Compound C5) is an irreversible, orally active pan-HER inhibitor with IC₅₀ values of 0.38, 1.6, 2.2 and 3.5 nM against EGFR, HER4, EGFR ^T790M/L858R and HER2, respectively. pan-HER-IN-1 induces apoptosis and shows antitumor activities .

HY-15246

Tovorafenib 2 Publications Verification TAK-580; MLN 2480; BIIB-024	Raf	Cancer
Tovorafenib (TAK-580, MLN 2480) is an orally active and selective inhibitor of *pan-Raf* kinase.

HY-107740

Pseudoisocyanine iodide 1,1'-Diethyl-2,2'-cyanine iodide; Decynium 22; Diethylcyanine iodide; Eastman 7851	Dopamine Transporter Monoamine Transporter Serotonin Transporter	Neurological Disease
Pseudoisocyanine (iodide) is a pan inhibitor of monoamine transporters and organic cation transporters with antidepressant-like activity .

HY-122616

PF-06273340	Trk Receptor	Inflammation/Immunology
PF-06273340 is a potent, selective, orally bioavailable and peripherally restricted pan Trk inhibitor .

HY-117967

MK-6169	HCV Protease	Infection
MK-6169 is a potent, pan-genotypic hepatitis C virus NS5A inhibitor .

HY-139535

Luxeptinib 1 Publications Verification CG-806	FLT3 Btk Apoptosis	Cancer
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent *pan-FLT3/pan-BTK* inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells .

HY-107549

KD 5170	HDAC	Cancer
KD 5170 is a pan inhibitor of histone deacetylases (HDACs) and exhibits broad spectrum antitumor activity in vitro and in vivo .

HY-13452

CID-1067700 5+ Cited Publications ML282	Ras	Inflammation/Immunology
CID-1067700 (ML282) is a pan GTPase inhibitor, and competitively inhibits Ras-related in brain 7 (Rab7) with a K_i of 13 nM.

HY-144069

Pan-Trk-IN-3	Trk Receptor Apoptosis	Cancer
Pan-Trk-IN-3 (Compound 11g) is a potent inhibitor of pan-Trk and their drug-resistant mutants with IC₅₀ values of 2, 3, 2, 21, 26, 5, 7 and 6 nM against TrkA, TrkB, TrkC, TrkA ^G595R, TrkA ^G667C, TrkA ^G667S, TrkA ^F589L and TrkC ^G623R, respectively. Pan-Trk-IN-3 displays excellent antitumor activity and induces apoptosis .

HY-18310

NIBR-17	PI3K	Cancer
NIBR-17 is a pan-class I PI3K inhibitor with suitable pharmacokinetic properties and inhibits tumor growth .

HY-159795

Claturafenib PF-07799933; ARRY-440	Raf	Cancer
Claturafenib ( PF-07799933) is an inhibitor of pan-mutant BRAF. Claturafenib inhibits pERK in HT29 cells with an IC₅₀ value of 1.6 nM .

HY-142656

PIM-IN-1	Pim	Cancer
PIM-IN-1 is a pan-PIM kinase inhibitor (KG-1, EC₅₀ = 61 nM; pS6, EC₅₀ = 71 nM).

HY-124592

BMT-052	HCV	Infection
BMT-052 is a pan-genotypic hepatitis C (HCV) NS5B polymerase primer grip inhibitor .

HY-133018

HCV-IN-7	HCV	Infection
HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC₅₀s of 3-47 pM. HCV-IN-7 shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 has anti-viral activity .

HY-133018A

HCV-IN-7 hydrochloride	HCV	Cancer
HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC₅₀s of 3-47 pM. HCV-IN-7 hydrochloride shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 hydrochloride has anti-viral activity .

HY-156529

pan-KRAS-IN-2	Ras	Cancer
pan-KRAS-IN-2 (compound 6) is a pan inhibitor of with IC₅₀s ≤10 nM for KRAS WT and mutants (G12D, G12C, G12V, G12S, G12A, Q61H), and ＞10 μM for KRAS G13D, respectively .

HY-163455

pan-HCN-IN-1	HCN Channel	Neurological Disease
pan-HCN-IN-1 (Compound J&J12e) is an inhibitor for hyperpolarization-activated and cyclic-nucleotide-gated 1 (HCN1) ion channel, with IC₅₀ of 58 nM. pan-HCN-IN-1 reduces the voltage sag response and enhances EPSP summation in ex vivo rats brain slices .

HY-123900

AZ12799734	TGF-β Receptor	Cardiovascular Disease
AZ12799734 is a selective, orally active TGFBR1 kinase inhibitor with an IC₅₀ of 47 nM. AZ12799734 is also a pan BMP and TGFβ inhibitor .

HY-13253

AMG 900 3 Publications Verification	Aurora Kinase	Cancer
AMG 900 is a potent and highly selective *pan-Aurora* kinases inhibitor with IC₅₀ of 5 nM, 4 nM and 1 nM for Aurora A, B and C, respectively.

HY-144102

HDAC-IN-29	HDAC	Cancer
HDAC-IN-29 (compound 13b) is a potent pan-HDAC inhibitor. HDAC-IN-29 shows antitumor activity .

HY-160124

Infigratinib-Boc	FGFR	Cancer
Infigratinib-Boc is a derivative of Infigratinib containing a Boc (t-Butyloxy carbonyl) group. Infigratinib is an ATP-competitive pan-FGFR inhibitor .

HY-16667

HLM006474 5 Publications Verification	Early 2 Factor (E2F)	Cancer
HLM006474 is a pan E2F inhibitor, which inhibits E2F4 DNA-binding with an IC₅₀ of 29.8 µM in A375 cells.

HY-112802

AZD3229	c-Kit	Cancer
AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. AZD3229 inhibits c-KIT with an IC₅₀ value of 223.3 nM .

HY-153226

BET-IN-14	Epigenetic Reader Domain	Cancer
BET-IN-14 is an orally active pan BET inhibitor (IC₅₀: 5.35 nM). BET-IN-14 has anti-cancer activity .

HY-111823

VH032 thiol VHL ligand 6	Ligands for E3 Ligase	Cancer
VH032 thiol (VHL ligand 6) is a VHL ligand, which binds to pan-BET inhibitor JQ1 via a linker to form PROTAC .

HY-118352

LB-205	HDAC	Neurological Disease
LB-205 is a pan-histone deacetylase inhibitor (HDACi). LB-205 can be used for the research of acute traumatic brain injury .

HY-W011254

Ac-VAD-CHO Ac-Val-Ala-Asp-CHO	Caspase	Cancer
Ac-VAD-CHO (Ac-Val-Ala-Asp-CHO) is a pan-caspase inhibitor. Ac-VAD-CHO inhibits dissipation of MMP and cytochrome c release in hypoxia-exposed cells .

HY-151372

*Protein kinase D inhibitor* 1**	PKD	Cancer
Protein kinase D inhibitor 1 (compound 17m) is a pan-PKD inhibitor, with IC₅₀ values ranging from 17 to 35 nM. Protein kinase D inhibitor 1 inhibits PKD-dependent cortactin phosphorylation .

HY-N6794

10Z-Hymenialdisine (Z)-Hymenialdisine; Hymenialdisine	AMPK VEGFR PDGFR	Cancer
10Z-Hymenialdisine ((Z)-Hymenialdisine) is a natural bioactive pyrrole alkaloid. 10Z-Hymenialdisine is a pan kinase inhibitor, and has anticancer activities .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library

295 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 295 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Target	Research Area

HY-P10243

Ac-VAD-CMK	Caspase	Neurological Disease
Ac-VAD-CMK is a pan inhibitor for caspase 1 .

HY-W011254

Ac-VAD-CHO Ac-Val-Ala-Asp-CHO	Caspase	Cancer
Ac-VAD-CHO (Ac-Val-Ala-Asp-CHO) is a pan-caspase inhibitor. Ac-VAD-CHO inhibits dissipation of MMP and cytochrome c release in hypoxia-exposed cells .

HY-164388

Z-VAD	Caspase Apoptosis Autophagy Necroptosis	Cardiovascular Disease Cancer
Z-VAD is a competitive, irreversible pan-caspase inhibitor. Z-VAD inhibits all 10 caspases, except for caspase-2 which is only weakly inhibited. Z-VAD decreases radiation-induced apoptosis. Z-VAD induces both autophagy and necrosis in irradiated MDA-MB-231 and H460 mouse xenografts. Z-VAD with radiation produces a significant tumor growth delay and shows dramatic antiangiogenic effect in cancer xenograft .

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6794

10Z-Hymenialdisine (Z)-Hymenialdisine; Hymenialdisine	Alkaloids Structural Classification Pyrrole Alkaloids Animals Classification of Application Fields Marine natural products Source classification Sponge Disease Research Fields Biological Pesticide Research Cancer Agricultural Research	AMPK VEGFR PDGFR
10Z-Hymenialdisine ((Z)-Hymenialdisine) is a natural bioactive pyrrole alkaloid. 10Z-Hymenialdisine is a pan kinase inhibitor, and has anticancer activities .

HY-10985

Marizomib Maximum Cited Publications 10 Publications Verification Salinosporamide A; NPI-0052	Marine natural products Source classification Marine microorganism	Proteasome
Marizomib (Salinosporamide A) is a second-generation, irreversible, brain-penetrant, *pan-proteasome* inhibitor. Marizomib inhibits the CT-L (β5), CT-T-laspase-like (C-L, β1) and trypsin-like (T-L, β2) activities of the 20S proteasome (IC₅₀=3.5, 28, and 430 nM, respectively) .

HY-W016420

Fosfomycin sodium 5+ Cited Publications MK-0955 sodium	Infection Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields	Bacterial Antibiotic
Fosfomycin (MK-0955) sodium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin sodium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .

HY-124586

Streptonigrin 1 Publications Verification Bruneomycin	Structural Classification Classification of Application Fields Source classification Pyridine Alkaloids Infection Quinones Alkaloids Monophenols Microorganisms Phenols Benzene Quinones Disease Research Fields Cancer	Protein Arginine Deiminase Antibiotic
Streptonigrin (Bruneomycin), a natural product produced by Streptomyces flocculus, possesses both anti-tumor and anti-bacterial activity. Streptonigrin acts as a *pan-PAD* inhibitor with IC₅₀s of 48.3±34.2 µM, 26.1±0.3 µM, 0.43±0.03 µM, and 2.5±0.4 µM for PAD1, PAD2, PAD3, and PAD4, respectively .

HY-N0234

Bavachinin 3 Publications Verification 7-O-Methylbavachin; Bavachinin A	Structural Classification Monophenols Flavonoids Classification of Application Fields Leguminosae Flavonones Source classification Phenols Psoralea corylifolia L. Plants Inflammation/Immunology Disease Research Fields	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N0234R

Bavachinin (Standard)	Structural Classification Monophenols Flavonoids Leguminosae Flavonones Source classification Phenols Psoralea corylifolia L. Plants	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

Cat. No.	Product Name	Chemical Structure

HY-124592

BMT-052
BMT-052 is a pan-genotypic hepatitis C (HCV) NS5B polymerase primer grip inhibitor .

HY-B1075AS

(Rac)-Fosfomycin (benzylamine)-13C3

(Rac)-Fosfomycin (benzylamine)- ¹³C₃ is the ¹³C labeled Fosfomycin[1]. Fosfomycin (MK-0955) is a broad-spectrum antibiotic. Fosfomycin can cross blood-brain barrier penetrating, and irreversibly inhibits an early stage in cell wall synthesis. Fosfomycin shows anti-bacteria activity for a range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria[2][3].

Cat. No.	Product Name		Classification

HY-156555

pan-KRAS-IN-3		Alkynes
pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor. pan-KRAS-IN-3 can be used for research of cancers . pan-KRAS-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163488

pan-KRAS-IN-14		Alkynes
pan-KRAS-IN-14 (compound 20) is a *Pan-KRAS* inhibitor (IC₅₀ =2.3 nM) .

HY-162446

pan-KRAS-IN-13		Alkynes
pan-KRAS-IN-13 (compound 2) is a potent inhibitor of KRAS, with IC₅₀s of 2.75 nM and 2.89 nM for G12D and G12V, respectively

HY-130985

9-Decyn-1-ol		PROTAC Synthesis Alkynes
9-Decyn-1-ol is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs. 9-Decyn-1-ol can be used to conjugate GDC-0068 with Lenalidomide to generate INY-03-041. INY-03-041 is a potent, highly selective and PROTAC-based pan-Akt degrader. INY-03-041 inhibits Akt1, Akt2 and Akt3 with IC₅₀s of 2.0 nM, 6.8 nM and 3.5 nM, respectively . 9-Decyn-1-ol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks